

## Supplementary methods

**Supplementary Table S1. Treatment-related serious adverse events**

<b>Adverse event, n (%)</b>	<b>Cohort A (n=37)</b>	<b>Cohort B (n=17)</b>
Any	9 (24.3)	5 (29.4)
Anaemia	0	1 (5.9)
Febrile neutropenia	0	1 (5.9)
Neutropenia	0	1 (5.9)
Lymphopenia	1 (2.7)	0
Pancytopenia	1 (2.7)	0
Thrombocytopenia	0	1 (5.9)
Colonic fistula	1 (2.7)	0
Diarrhoea	1 (2.7)	0
Vomiting	1 (2.7)	0
Enteritis	0	1 (5.9)
Pancreatitis	0	1 (5.9)
Pneumonitis	1 (2.7)	1 (5.9)
Pulmonary embolism	0	1 (5.9)
Myocardial infarction	1 (2.7)	0
Pericardial effusion	1 (2.7)	0
Neutrophil count decreased	1 (2.7)	0

**A phase 1 dose-expansion study of trifluridine/tipiracil with oxaliplatin – 06 July 2021**

<i>Staphylococcus</i> test positive	1 (2.7)	0
Deep vein thrombosis	1 (2.7)	0
Hypertension	1 (2.7)	0
Abdominal abscess	1 (2.7)	0
Stoma site haemorrhage	1 (2.7)	0
Muscular weakness	0	1 (5.9)
Malignant neoplasm progression	1 (2.7)	0
Female genital tract fistula	1 (2.7)	0

## **A phase 1 dose-expansion study of trifluridine/tipiracil with oxaliplatin – 06 July 2021**

### **Supplementary Figure S1**

Study schema. A Bayesian 3-stage method was used for the dose-expansion phase. If a certain number of responses (CR and PR) were shown at each interim analysis, patient recruitment was continued. CR, complete response; PR, partial response.

### **Supplementary Figure S2**

Heat map showing biomarker parameters in patients in Cohort B. Columns represent patients and rows biomarker parameters. Biomarker parameters (from top to bottom of the figure) were: PDL1 expression (0%, 1%, 5%), CD8+ expression (0%, 20%, 40%, 60%, 80%, 100%), immunoscore (0, 1, 2), and mean Z-scores for genes related to the inflammatory response, mean Z-scores for T-cell function and activation, mean Z-scores for IFN $\gamma$  signature, and mean Z-scores for the tumour inflammation signature. Parameter measures were standardised (centred and scaled) within columns for the purposes of visualisation. Bsl, baseline; C4, cycle 4; CD8, CD8 T lymphocytes; IFN $\gamma$ , interferon gamma; NE, not evaluated; PD, progressive disease; PD-L1, programmed death ligand 1; PR, partial response; SD, stable disease.

## **A phase 1 dose-expansion study of trifluridine/tipiracil with oxaliplatin – 06 July 2021**

### **Supplementary Figure S3**

Heat map of Z-scores of gene expression for genes related to the inflammatory response in patients in Cohort B. Biopsy samples were taken at baseline and/or at cycle 4. Columns represent patients and rows genes. Expression levels have been standardised (centred and scaled) within columns for the purposes of visualisation. Bsl, baseline; BOR, best overall response; C4, cycle 4; NE, not evaluated; PD, progressive disease; PR, partial response; SD, stable disease; SUBJID, subject identifier; TRTDUR, treatment duration.

### **Supplementary Figure S4**

Heat map of Z-scores of gene expression for genes related to T-cell function and activation in patients in cohort B. Biopsy samples were taken at baseline and/or at cycle 4. Columns represent patients and rows genes. Expression levels have been standardised (centred and scaled) within columns for the purposes of visualisation. Bsl, baseline; BOR, best overall response; C4, cycle 4; NE, not evaluated; PD, progressive disease; PR, partial response; SD, stable disease; SUBJID, subject identifier; TRTDUR, treatment duration.

### **Supplementary Figure S5**

Heat map of Z-scores of gene expression for genes related to interferon gamma signature in patients in cohort B. Biopsy samples were taken at baseline and/or at cycle 4. Columns represent patients and rows genes. Expression levels have been standardised (centred and scaled) within columns for the purposes of visualisation. Bsl, baseline; BOR, best overall response; C4, cycle 4; NE, not evaluated; PD, progressive disease; PR, partial response; SD, stable disease; SUBJID, subject identifier; TRTDUR, treatment duration

## **A phase 1 dose-expansion study of trifluridine/tipiracil with oxaliplatin – 06 July 2021**

### **Supplementary Figure S6**

Heat map of Z-scores of gene expression for genes related to tumour inflammation signature in patients in cohort B. Biopsy samples were taken at baseline and/or at cycle 4. Columns represent patients and rows genes. Expression levels have been standardised (centred and scaled) within columns for the purposes of visualisation. Bsl, baseline; BOR, best overall response; C4, cycle 4; NE, not evaluated; PD, progressive disease; PR, partial response; SD, stable disease; SUBJID, subject identifier; TRTDUR, treatment duration